Over a decade ago, it was proven that the combination of trastuzumab with everolimus can rescue cancer cells from trastuzumab resistance caused by alterations in the PI3K/AKT/mTOR signalling pathway, with greater efficacy than either agent alone [28]. This evidence concerns the gene PIK3CA and cancer.